The Lift Line
“A bill that fell by 77 per cent in a single visit shows what India has already built.” (T.C. Suseel Kumar and R. Sudhakar, The Hindu, 19 November 2026)
Why This Editorial Matters for Your Exam
In the news: on 19 November 2026, T.C. Suseel Kumar, former Managing Director of LIC, and R. Sudhakar, former Executive Director of LIC, argued in The Hindu’s “Text and Context” pages that the Jan Aushadhi scheme works but has not caught on as widely as it should, and set out six steps to expand it.
For context, the piece arrives days after the Union Health Ministry released the National Health Accounts for 2023-24 on 15 November, which track how much of the health bill households pay themselves (our 16 November roundup). Medicine prices came up earlier, in the context of trade margins, in our 1 October editorial on trade margins and drug pricing.
GS Paper 2: government schemes for health, access to medicines, and the role of regulators such as the National Medical Commission. GS Paper 3: the pharmaceutical sector and inclusive growth. Prelims hooks: the scheme’s full name, its ministry and agency, and its numbers.
The Crux in 60 Words
Jan Aushadhi Kendras sell generics far below branded prices, and the network has grown fast. But the authors argue the scheme is still small for India: many people do not know it, doctors prescribe brands, quality data is thin and stocks run short. They want a national survey, published testing, stock tracking, doctors on board and dedicated funding.
The authors argue that Jan Aushadhi already cuts medicine bills sharply, but remains small for a country of India’s size, and that a national survey, transparent quality data, steady stocks, doctors’ confidence and a dedicated allocation are needed to scale it.
- They say the network is small beside the roughly 12 lakh chemists and druggists reported by the chemists’ association, and that Kendras may sit in less busy areas.
- They cite a small Port Blair study in which only a third of 200 outpatients had heard of the scheme and only 6 per cent had ever asked a doctor for generics.
- They note that the National Medical Commission’s order to prescribe by generic name was put on hold after doctors’ bodies objected on quality and autonomy.
- They say stock-outs erode trust, and that the Government publishes no data on why people use or avoid the Kendras.
The scheme is already large and growing: the network grew from 80 Kendras in 2014 to more than 20,000 by mid-2026, and every batch is tested before sale. Doctors’ doubts about quality are not baseless either, which is why the authors themselves call for published testing.
A national survey with an independent academic partner, regular publication of batch-testing results with period, method and laboratory, online stock tracking, renewed dialogue with doctors before restoring generic prescribing, and a dedicated allocation, as the authors propose.
Background and Context
The scheme in numbers
All figures below are the Government’s, from the Press Information Bureau (PIB):
| Indicator | Figure | As of |
|---|---|---|
| Jan Aushadhi Kendras | 80 in 2014; 20,149 | 30 June 2026 (PIB, 28 July 2026) |
| Target | 25,000 Kendras | by March 2027 |
| Basket | 2,110 medicines, 315 surgical items, 29 therapeutic categories | PIB, 7 March 2026 |
| Price | generally 50 to 80 per cent below comparable brands | PIB, 7 March 2026 |
| Sales | Rs 7.29 crore in 2014; Rs 2,252.19 crore | 2025-26 |
| Estimated savings to citizens | about Rs 45,000 crore | over the last 12 years (PIB, 28 July 2026) |
| Daily visitors | about 15 lakh, on average | PIB, 28 July 2026 |
For context on growth, a Government annexure released by PIB put the network at 17,990 Kendras on 31 December 2025, and PMBI’s own newsletter, JA Varta (Edition 49, 14 August 2026), counts 20,547 till 31 July 2026. As background, an earlier target, 20,000 Kendras by 31 March 2026, was stated in a Lok Sabha reply of July 2025. For 2024-25 PIB gave sales of Rs 2,022.47 crore and savings of about Rs 8,000 crore. The savings are estimates made by comparing against the prices of branded medicines.
How quality is policed
PIB says medicines are procured only from manufacturers compliant with WHO Good Manufacturing Practice (WHO-GMP), and each batch is tested at laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). A December 2025 Lok Sabha reply added that samples are drawn from 100 per cent of batches at PMBI’s warehouses. The same reply gave batches purchased and batches reported not of standard quality (NSQ) by regulators: for 2024-25, 18,686 and 46; for 2023-24, 13,000 and 61. A batch found NSQ is recalled, and suppliers face penalties such as forfeiture and blacklisting. The supply chain then ran through five warehouses and 39 distributors, and an incentive to stock 200 commonly used medicines has applied since September 2024.
The health-spending picture
The National Health Accounts 2023-24 (PIB, 15 November 2026) show the OOPE share falling from 64.2 per cent in 2013-14 to 42.7 per cent in 2023-24. In the context of public spending, government health expenditure was 1.43 per cent of GDP in 2022-23, up from 1.15 per cent in 2013-14 (PIB, 27 May 2026); the 2023-24 release gives no GDP share. The column dates this figure to 2023-24; PIB gives it for 2022-23.
The Analysis
1. The bill that started it. The authors open with one of their own households: a monthly medicines bill of about Rs 2,900 fell to Rs 663 at a Jan Aushadhi outlet. “The bill is not a fluke,” they write; it is “the visible end of a long chain of efforts” to make medicines affordable, and it “banks on a manufacturing base that has made India the largest supplier of generic medicines in the world”.
2. Small for India’s size. Their central claim is that a scheme launched in 2008 “has not caught on as widely as a country of India’s size and income levels would warrant”. Against “a reported 12 lakh chemists and druggists”, a figure they take from the chemists’ association, the Kendras are about 1.7 per cent; the authors call this “a comparison of scale rather than an exact count of shops”. They add that Kendras may sit in less busy areas, perhaps to save on rent.
3. Awareness and image. In “a small study of 200 outpatients in Port Blair”, only a third had heard of the scheme and more than half did not know what the outlets sell. The authors concede the study “cannot be construed as a national sample” and use that very weakness to argue for a national survey. They also note a perception that the Kendras “are for the poor”.
4. The doctor decides. A patient buys what the prescription names. The authors say that when the National Medical Commission ordered prescriptions by generic name, doctors’ bodies objected “citing autonomy, accountability and quality, and the order was put on hold”. In the Port Blair study only 6 per cent had ever asked a doctor for generics. They grant that doctors “are not wrong when they want assurances about the quality”.
5. Trust: quality and stock. The authors want quality claims made checkable: testing results published “with the period, the method and the laboratories named”. They report that the Indian Pharmacopoeia Commission “has agreed to test random batches”. On stock, they cite reports of Kendras running out, and admit, “We are not sure whether this is indeed the case”, which is again an argument for measurement.
6. Jan Aushadhi for all. Unlike a subsidised general hospital, where wealthier patients may crowd out poorer ones, a store frequented by everyone gains demand, sales and stock depth. Universal use, they argue, makes the shop stronger rather than the queue longer.
7. The money. The authors say medicines make up “roughly 60 to 70 per cent” of household OOPE, that outpatient drugs are largely outside insurance such as Ayushman Bharat PM-JAY, and that the National Health Policy’s target of 2.5 per cent of GDP by 2025 “remains unfulfilled”. They want “a dedicated allocation” for Jan Aushadhi as public health spending rises.
Their six steps: a national survey by the Department of Pharmaceuticals and the Health Ministry with an independent academic partner (the precondition); published random-batch testing; online stock tracking; convincing doctors, then bringing back the generic-prescribing mandate, with bioequivalence status shown on labels; promoting the Kendras to all; and a dedicated allocation.
Data and Institutions Vault
Prelims-grade facts:
The scheme:
- Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP): Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
- Implementing agency: Pharmaceuticals and Medical Devices Bureau of India (PMBI)
- Launched November 2008; revamped September 2015 as Pradhan Mantri Janaushadhi Yojana; later renamed PMBJP
- Kendras: 80 in 2014; 20,149 till 30 June 2026 (PIB)
- Basket: 2,110 medicines and 315 surgical items in 29 therapeutic categories (PIB, March 2026)
Money and use:
- Sales 2025-26: Rs 2,252.19 crore; estimated savings about Rs 45,000 crore over 12 years (PIB, July 2026)
- About 15 lakh visitors a day on average (PIB, 28 July 2026)
- Operators: 20 per cent trade margin on MRP; monthly incentive up to Rs 20,000, total limit Rs 5 lakh
- One-time Rs 2 lakh for women, Divyang and SC/ST operators and aspirational, Himalayan, island and North-Eastern areas
Health spending (National Health Accounts):
- OOPE share of health spending: 64.2 per cent (2013-14) to 42.7 per cent (2023-24)
- Government health expenditure: 1.43 per cent of GDP in 2022-23
The traps:
- 25,000 Kendras by March 2027 is a target, not an achievement
- Savings are Government estimates against branded prices, not audited figures
- PMBI implements the scheme; the Department of Pharmaceuticals, not the Health Ministry, runs it
The Debate
The case for the authors. The scheme’s own numbers show a gap between reach and potential: Kendras are growing, and the Government has data on outlets, footfall and sales, but the authors found no information on why people use or avoid them. Without that, expansion is guesswork. Published testing would also answer the doctors’ main objection.
The other side. The scheme is not small in absolute terms: the network has grown from 80 Kendras in 2014 to more than 20,000, and every batch is sampled before sale. The regulators’ NSQ counts in the PIB reply are a few dozen batches a year against thousands bought. Much of the column’s case rests on one household bill and one small study, as the authors themselves admit, and the chemists’ total is an association’s estimate.
The balanced verdict. Both sides want the same thing: evidence. A national survey and open quality data cost little beside the savings the scheme already claims, and they would settle the doctors’ doubts and guide where the Kendras still to come under the 2027 target should go.
How to Think About This
Use the “access, affordability, assurance, awareness” lens for any question on medicines:
- Access: is there an outlet nearby, and is it stocked?
- Affordability: how far below the brand is the price, and who pays for outpatient drugs?
- Assurance: can quality be shown, batch by batch, with published results?
- Awareness: do patients and, above all, prescribing doctors know and trust the product?
Then separate the record from the reading: PIB’s counts, targets and estimates are the record; the chemists’ total, the Port Blair study and the share of medicines in OOPE are figures the authors cite.
Diagram-in-Words
Doctor’s prescription → patient’s choice of shop → Kendra stock → batch-tested generic → lower bill. At each step the authors place a fix: generic prescribing, awareness, stock tracking, published testing and funding.
Read left to right: the chain breaks at whichever link a patient does not trust.
Medicines form a large share of household out-of-pocket health spending in India. Examine the role of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana in reducing this burden, and suggest measures to widen its reach. (250 words)
The share of out-of-pocket expenditure (OOPE) in health spending fell from 64.2 per cent in 2013-14 to 42.7 per cent in 2023-24 (National Health Accounts), yet households still pay much of their health bill themselves. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana, run by the Department of Pharmaceuticals, attacks the medicine part of that bill by selling quality generics at low prices.
Reach. The network grew from 80 Kendras in 2014 to 20,149 by 30 June 2026, with a target of 25,000 by March 2027.
The basket covers 2,110 medicines and 315 surgical items across 29 therapeutic categories, priced generally 50 to 80 per cent below comparable brands. Sales rose from Rs 7.29 crore in 2014 to Rs 2,252.19 crore in 2025-26, with estimated savings to citizens of about Rs 45,000 crore over 12 years.
Design. Kendras run on a franchisee model with a 20 per cent trade margin and incentives, including a one-time grant for women, Divyang and SC/ST operators and those in aspirational, Himalayan, island and North-Eastern areas.
Quality. Supplies come only from WHO-GMP-compliant manufacturers and every batch is tested in NABL-accredited laboratories.
Gaps. Awareness is uneven; doctors prescribe by brand and resist generic-name mandates citing quality; stock-outs erode trust; and outpatient medicines lie largely outside insurance cover.
Government health expenditure was 1.43 per cent of GDP in 2022-23.
Jan Aushadhi is one of the most direct tools for cutting out-of-pocket spending. A national demand survey, public batch-testing data, real-time stock management, engagement with doctors and higher public health spending can turn a successful network into a habit for every household.
Interview Angle
"Jan Aushadhi medicines cost far less than branded ones, yet many patients and doctors still prefer brands. If you were posted as a District Collector, how would you raise trust in and use of the local Jan Aushadhi Kendras?"
Takeaway Box
- Core idea: cheap generics cut OOPE only if doctors prescribe them, patients trust them and the shelf has them.
- Prelims hooks: PMBJP; Department of Pharmaceuticals; PMBI; the size of the basket; the Kendra target for March 2027.
- Ethics angle: a doctor’s autonomy against the patient’s right to affordable care; trust built on evidence.
- Probable question: “How can generic medicines reduce out-of-pocket health expenditure in India? Discuss with reference to the Jan Aushadhi scheme.” (GS2, 150 words)
Sources:
- The Hindu, “The need to expand Jan Aushadhi”, Text and Context, 19 November 2026
- PIB, Ministry of Chemicals and Fertilizers: releases on PMBJP, 7 March, 21 March and 28 July 2026; Lok Sabha reply, 12 December 2025; PMBJP factsheet, March 2023
- PIB, Ministry of Health and Family Welfare: National Health Accounts 2022-23 (27 May 2026) and 2023-24 (15 November 2026)
- PMBI, JA Varta, Edition 49, 14 August 2026
Cite this page: Jan Aushadhi Scheme: The Need to Expand Generic Access — Ujiyari.com | Free UPSC & State PCS Editorial Analysis